Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ye Chan Yoon"'
Publikováno v:
Future oncology
SB8 is a biosimilar of bevacizumab based on its similarity demonstrated by physicochemical, functional, non-clinical and clinical studies. Supported by the concept of extrapolation, SB8 was authorized and is used in a similar manner across all types
Autor:
Xavier Pivot, Mark D Pegram, Javier Cortes, Diana Lüftner, Gary H Lyman, Giuseppe Curigliano, Igor M Bondarenko, Mikhail Dvorkin, Jin Hee Ahn, Seock-Ah Im, Maria Litwiniuk, Yaroslav V Shparyk, Gwo Fuang Ho, Nikolay V Kislov, Marek Wojtukiewicz, Tomasz Sarosiek, Yee Soo Chae, Jin Seok Ahn, Hyerin Jang, Sujung Kim, Jiwon Lee, Soo Young Lee, Ye Chan Yoon
Publikováno v:
Cancer Research. 82:P2-13
Background: SB3 (trastuzumab-dttb) is a biosimilar approved globally based on its similarity with reference trastuzumab (TRZ) demonstrated by thorough comparability exercises in analytical, biological, and clinical studies. In a randomized, double-bl
Autor:
Younsoo Kim, Xavier Pivot, Igor Bondarenko, Diana Lüftner, Giuseppe Curigliano, Chul Kim, Javier Cortes, Ye Chan Yoon, Gary H. Lyman, Mark D. Pegram
Publikováno v:
European journal of cancer (Oxford, England : 1990). 120
Background We assessed long-term cardiac safety and efficacy in patients with human epidermal growth factor receptor 2–positive early breast cancer treated with a trastuzumab biosimilar (SB3) or its reference product, trastuzumab (TRZ), in a phase
Autor:
Younsoo Kim, Xavier Pivot, Mikhail Dvorkin, Chul Kim, Diana Lüftner, Hope S. Rugo, Mark D. Pegram, Giuseppe Curigliano, Javier Cortes, Ye Chan Yoon, Gary H. Lyman, Igor Bondarenko
Publikováno v:
Journal of Clinical Oncology. 38:578-578
578 Background: SB3 was approved in the US and EU as a biosimilar of reference trastuzumab (TRZ). Here, we report 4-year cardiac safety and survival outcomes. Methods: After completing neoadjuvant-adjuvant therapy in patients with HER2 positive early
Autor:
Igor Bondarenko, Diana Lüftner, Javier Cortes, Xavier Pivot, Ye Chan Yoon, Gary H. Lyman, Giuseppe Curigliano, Jae Yun Lim, Younsoo Kim, Mark D. Pegram
Publikováno v:
Journal of Clinical Oncology. 37:580-580
580 Background: SB3 is an approved biosimilar of reference trastuzumab (TRZ). At additional 2-year follow-up after completing neoadjuvant and adjuvant treatment, there was a difference in event-free survival (EFS), but no difference in overall surviv
Publikováno v:
Annals of Oncology. 29:viii71
Autor:
S. Song, Jae Yun Lim, J. Cortes Castan, Xavier Pivot, Ye Chan Yoon, Giuseppe Curigliano, Mark D. Pegram
Publikováno v:
Annals of Oncology. 29:viii69